Clone: 8E6
Background: Myeloperoxidase (MPO) is a glycoprotein present in the azurophil (primary) granules of myeloid cells, which appears in the myeloblast stage of myeloid cell differentiation. MPO is he most common functional protein of myeloid cells and is involved in the inflammatory response. It helps to kill microbes by breaking down peroxide in the presence of halide ions, contributing to the bactericidal function of granulocytes. The primary translation product of MPO undergoes glycosylation with production of the 89 kDa heme-free apopro-MPO form followed by incorporation of heme and conversion into the enzymatically active pro-MPO form. Subsequently, pro-MPO becomes targeted to azurophil granules where final processing occurs to produce mature dimeric MPO consisting of the 59-64 kDa MPO ?-chain and the 14 kDa MPO ?-chain. The MPO-C2 mAb (clone 8E6) recognizes virtually all myelomonocytic cells including AML blasts. The MPO-C2 mAb permits the identification and enumeration of myeloid cells in normal and malignant human blood and bone marrow using flow cytometry. Results must be interpreted by a certified professional before final interpretation. Analyses performed with this antibody should be paralleled by positive and negative controls. If unexpected results are obtained which cannot be attributed to differences in laboratory procedures, please contact us.
Purification Method: Purified by Chromatography
Specificity: The MPO-C2 mAb (clone 8E2) reacts with human myeloperoxidase (MPO) expressed by normal and malignant myelomonocytic cells. The sensitivity of MPO-C2 mAb is determined by staining well-defined blood samples from representative donors with serial-fold mAb dilutions to obtain a titration curve that allows relating the mAb concentration to the percentage of stained cells and geometric MFI (mean fluorescence intensity). For this purpose, a mAb-concentration range is selected to include both the saturation point (i.e. the mAb dilution expected to bind all epitopes on the target cell) and the detection threshold (i.e. the mAb dilution expected to represent the least amount of mAb needed to detect an identical percentage of cells). In practice, 50 µl of leukocytes containing 10^7cells/ml are stained with 20 µl mAb of various dilutions to obtain a titration curve and to identify the saturation point and detection threshold. The final concentration of the product is then adjusted to be at least 3-fold above the detection threshold. In addition and to control lot-to-lot variation, the given lot is compared and adjusted to fluorescence standards with defined intensity.
Formulation: PBS pH 7.2, 1% BSA, 0.05% NaN3
References: 1. Andersson, E., Hellman, L., Gullberg, U. & Olsson, I. (1998) J Biol Chem 273, 4747-53. 2. Catovsky, D., Matutes, E., Buccheri, V., Shetty, V., Hanslip, J., Yoshida, N. & Morilla, R. (1991) Ann Hematol 62, 16-21. 3. Cramer, E., Pryzwansky, K. B., Villeval, J. L., Testa, U. & Breton-Gorius, J. (1985) Blood 65, 423-32. 4. Gullberg, U., Andersson, E., Garwicz, D., Lindmark, A. & Olsson, I. (1997) Eur J Haematol 58, 137-53. 5. Imamura, N. (1998) Am J Hematol 58, 241-3. 6. Knapp, W., Majdic, O. & Strobl, H. (1993) Recent Results Cancer Res 131, 31-40. 7. Koeffler, H. P., Ranyard, J. & Pertcheck, M. (1985) Blood 65, 484-91. 8. Lanza, F., Latorraca, A., Moretti, S., Castagnari, B., Ferrari, L. & Castoldi, G. (1997) Cytometry 30, 134-44. 9. Murao, S., Stevens, F. J., Ito, A. & Huberman, E. (1988) Proc Natl Acad Sci U S A 85, 1232-6. 10. Nakase, K., Sartor, M. & Bradstock (1998) Cytometry 34, 198-202. 11. Nauseef, W. M. (1990) Hematol Pathol 4, 165-78. 12. Nauseef, W. M., Olsson, I. & Arnljots, K. (1988) Eur J Haematol 40, 97-110. 13. Srivastava, C. H., Rado, T. A., Bauerle, D. & Broxmeyer, H. E. (1991) J Immunol 146, 1014-9. 14. Strobl, H. & Knapp, W. (2004) J Biol Regul Homeost Agents 18, 335-9. 15. Strobl, H., Takimoto, M., Majdic, O., Fritsch, G., Scheinecker, C., Hocker, P. & Knapp, W. (1993) Blood 82, 2069-78. 16. Tsuruta, T., Tani, K., Hoshika, A. & Asano, S. (1999) Leuk Lymphoma 32, 257-67. 17. van der Schoot, C. E., Daams, G. M., Pinkster, J., Vet, R. & von dem Borne, A. E. (1990) Br J Haematol 74, 173-8. 18. van der Schoot, C. E., von dem Borne, A. E. & Tetteroo, P. A. (1987) Acta Haematol 78 Suppl 1, 32-40. 19. Zaki, S. R., Austin, G. E., Swan, D., Srinivasan, A., Ragab, A. H. & Chan, W. C. (1989) Blood 74, 2096-102.
UniProt: P05164
Caution: For professional users only. This reagent contains sodium azide. To avoid the development of hazardous conditions, reagents containing azide should be diluted in running water prior to be discarded. Similar to the work with other biological products, proper handling procedures are recommended.
English
Deutsch
